Merck & Co. (NYSE:MRK) is a prominent American multinational pharmaceutical company many investors know for its brand-name ...

Merck on Tuesday missed earnings estimates, lowered its guidance for this year’s earnings, and withdrew a target for sales of ...

Merck's latest earnings call revealed a mix of growth and pain points for the pharmaceutical giant.

Investors have taken to punishing pharma companies that appear unable to gauge demand for their top products. Consider Pfizer. The company’s inability to accurately project demand for its Covid-19 ...

Shares of Merck are sliding in early trading after the drugmaker surprised Wall Street with a lower-than-expected 2025 sales ...

With a volume of 12,212,671, the price of MRK is down -1.44% at $88.38. RSI indicators hint that the underlying stock may be ...

Executives pulled back on a 2030 sales target of $11 billion as demand for the HPV shot shrinks amid China market turmoil.

The healthcare giant is dealing with the fast-approaching patent cliff for its most important product, cancer medicine ...

Merck ( MRK) reported fourth quarter and full year earnings Tuesday, in line with Wall Street estimates. The bad news: Its ...

Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks ...

As Moderna maps out a more cautious future amid lower-than-expected sales of its current products, the company is bolstering ...

Shares of Merck are sliding in early trading after ... due partly to a pause in shipments of one of its top-selling products to China Shares of Merck slid Tuesday after the drugmaker surprised ...